Skip to main content
. Author manuscript; available in PMC: 2011 Apr 1.
Published in final edited form as: J Neuropathol Exp Neurol. 2010 Apr;69(4):356–371. doi: 10.1097/NEN.0b013e3181d53d98

Figure 4.

Figure 4

Paxillin expression in control and Alzheimer disease (AD) hippocampi. (A) Low-power magnification reveals paxillin immunoreactivity in the alveus/white matter (WM) tracts and the stratum lacunosum (SL) layer in both control (a) and AD (b) subjects. In the hilus/CA4 of control subjects, paxillin is localized to reactive astrocytes and neuropil (c). AD hippocampus exhibits elevated paxillin immunoreactivity in reactive astrocytes throughout the hippocampus and within plaques (d). Higher power magnification of CA1 pyramidal neurons reveals punctate nuclear paxillin distribution in control (e) but not AD (f). Scale bars: a, b = 500 µm; c = 100 µm; d = 50 µm; e, f = 25 µm. (B) Mann Whitney statistical test comparing paxillin levels in control vs. AD subjects.